| Cancer name | Kidney Renal Clear Cell Carcinoma |
| Cancer Type | KIRC |
| Immunotherapy type | Immune Checkpoint Therapy |
| Treatment | Atezolizumab |
| Drugstatus | Approved |
| Drugbank ID | DB11595 |
| Checkpoints | PD-1 |
| Signature Type | Protein |
| Signature | ferritin |
| Official Symbol | FTH1 |
| Mode of action | TRAN_R_DOWN |
| Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals. | |
| Experimental | clinical trail |
| Description | An important aspect of this study was the evaluation of immunologic correlates to atezolizumab monotherapy in RCC to better understand the biology of response and resistance to atezolizumab. For example, plasma VEGFA, a known tumor burden marker in RCC, was decreased in responders but was stable inpatients with stable disease or PD. Inaddition, on-treatment decreases in acute-phase proteins,including ferritin, complement C3, vitamin D–binding protein,and macrophage inflammatory protein-1a were significantly associated with longer OS. Lower baseline levels of multiple acute-phase proteins, including von Willebrand factor,serum amyloid P component,a-1-antitrypsin, and fibrinogen(negative prognostic factors in RCC) were also associated with longer OS. |
| PMID | 26755520 |
| Title | Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. |